NVIC Articles

Disease-Vaccine-Landing-Page

Disease-Vaccine-Landing-Page

Latest articles

Browse Articles

Placeholder image
Page

Both RotaTeq and ROTARIX are live virus vaccines and it is possible for a vaccine recipient to shed the vaccine-strain virus to others. Persons most at risk for developing rotavirus...

Placeholder image
Page

In the U.S., researchers have reported that rotavirus vaccines have decreased the number of rotavirus infections requiring medical attention. However, researchers also note that since vaccine’s introduction, the G12P[8] rotavirus...

Placeholder image
Page

According to the package insert2, from infancy through one year, ROTARIX efficacy against severe rotavirus gastroenteritis was 84.7 percent in infants who received two vaccine doses, and 81 percent among...

Placeholder image
Page

According to the package insert1, RotaTeq vaccine will prevent about 74 percent of rotavirus cases, about 98 percent of severe cases, and about 96 percent of hospitalizations due to rotavirus.No...

Placeholder image
Page

On June 11, 2010, the CDC issued revised recommendations and added severe combined immunodeficiency (SCID) as a contraindication to receiving rotavirus vaccines. SCID is a group of rare disorders caused...

Placeholder image
Page

On March 22, 2010, the FDA announced that an independent U.S. academic research team had found DNA from porcine circovirus 1 (PCV1) in the ROTARIX vaccine. The FDA recommended that...

Placeholder image
Page

Contraindications to receiving rotavirus vaccines included a history of severe allergic reaction to a previous vaccine dose or to any component of the vaccine. ROTARIX was not recommended for infants...

Placeholder image
Page

On April 3, 2008, the FDA approved ROTARIX, a second live oral rotavirus vaccine for use in infants six through 24 weeks of age. Manufactured by GlaxoSmithKline, this vaccine was...

Placeholder image
Page

The CDC’s ACIP, which had begun discussions on RotaTeq in 2005, voted in February 2006 for all infants to receive 3 vaccine doses at 2, 4, and 6 months of...

Placeholder image
Page

Wyeth-Lederle was not the only pharmaceutical company working on a rotavirus in the 1990s. Both Merck and GlaxoSmithKline were actively in the development stages of a vaccine. On February 3,...

Topics
Select disease / vaccine